 |
 |
|||||
  |
 |
 |
 |
 |
 |
|
 |
|
Fintan Steele joined Feinstein Kean Healthcare in 2006 as the Senior Vice President for the Molecular Medicine Practice, and was promoted to Executive Vice President of the Life Sciences group in 2007. His background includes 15+ years of experience in communicating the science and implications of genetics and genomics to a variety of audiences. Prior to joining Feinstein Kean, Fintan was the Director of Communications for the Broad Institute of MIT and Harvard, the new collaborative effort by MIT, Harvard and its affiliated hospitals and the Whitehead Institute founded to bring the power of genomics to medicine. He previously worked as the Global Head of Communications for the Novartis Institutes for BioMedical Research, the research division of Novartis. In addition to his communications director experiences, Fintan held several editorial positions for public and private scientific publishers, including News and News & Views editor for Nature Medicine, Executive Editor of the Journal of Clinical Investigation, and Executive Editor of Genomics and of Molecular Therapy. He earned his doctorate from the University of Notre Dame in South Bend, Ind., and completed postdoctoral fellowships at the National Eye Institute, National Institutes of Health and at Johns Hopkins School of Medicine. Fintan also holds a Masters of Divinity degree from St. Meinrad School of Theology as well as a Masters of Arts in Medical Ethics/Religious Studies from Indiana University, where he focused on ethical issues in genetic engineering. He has published many articles, both on scientific findings and the implications of scientific findings for those affected by them. |
|
||||
 |
||||||
|
|
|
|
|
